A Pilot Study of Fludarabine Plus Cyclophosphamide in Refractory Severe Aplastic Anemia

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
National Institutes of Health Clinical Center (CC) ( National Heart, Lung, and Blood Institute (NHLBI) )
ClinicalTrials.gov Identifier:
NCT01187017
First received: August 20, 2010
Last updated: February 8, 2013
Last verified: July 2012
  Purpose

Background:

  • Severe aplastic anemia (SAA) can lead to problems with bone marrow health and result in low blood cell counts, which require frequent transfusions. Standard initial treatment for SAA involves injections of antithymocyte globulin (ATG) plus cyclosporine (CsA). Patients with SAA who do not respond to initial treatment with ATG (refractory) have a high risk of dying without additional treatment. In these cases, for those who do not have a matched bone marrow transplant donor there is no well-defined standard therapy. In our experience with patients who do not respond to horse ATG + CsA, only about one-third of patients who are re-treated with rabbit ATG + CsA improve. Experience with cyclophosphamide in the treatment of refractory severe aplastic anemia suggests that this drug is able to improve blood counts in about 50% of cases. However, the cyclophosphamide regimen has been associated with a significant infection risk (mostly caused by fungus) in studies conducted over 10 years ago due to the lowering of the white blood cell levels.
  • Better antibiotic drugs against fungus have been developed and are widely used to treat patients who have low white blood cell counts and are at risk of developing infections. In SAA patients in particular, these newer antibiotics have had a large impact in preventing and treating fungus infections. Researchers are revisiting the use of cyclophosphamide at lower doses to minimize its side effects given in combination with another immune suppressant, fludarabine.

Objectives:

- To determine the safety and effectiveness of the combination of fludarabine plus cyclophosphamide in treating severe aplastic anemia that has not responded to initial treatments.

Eligibility:

- Individuals at least 2 years of age who have severe aplastic anemia that has not improved after treatment with horse ATG or both horse and rabbit ATG.

Design:

  • After initial screening, medical history, and blood tests, participants will be admitted to the inpatient unit at the National Institutes of Health Clinical Center.
  • Participants will receive 2 days of cyclophosphamide, followed by 5 days of fludarabine.
  • Participants will also receive antibiotics and other drugs to protect against bacterial, fungal, and viral infections. Participants will take these drugs regularly until their white blood cell counts improve.
  • After discharge from the clinical center, participants will have follow-up evaluations at 3 months, 6 months, and annually for 5 years. Evaluations will include blood samples and periodic bone marrow biopsies.

Condition Intervention Phase
Aplastic Anemia
Neutropenia
Pancytopenia
Severe Aplastic Anemia
Refractory Severe Aplastic Anemia
Drug: Cyclophosphamide
Drug: Fludarabine
Phase 1
Phase 2

Study Type: Interventional
Study Design: Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: A Pilot Study of Fludarabine Plus Cyclophosphamide in Refractory Severe Aplastic Anemia

Resource links provided by NLM:


Further study details as provided by National Institutes of Health Clinical Center (CC):

Primary Outcome Measures:
  • The primary objective is to evaluate the safety and activity profile of Flu/Cy in SAA.-The primary safety endpoint will be toxicity profile in the 6 months following Flu/Cy-The primary efficacy endpoint is response rate at 6 months

Secondary Outcome Measures:
  • Secondary endpoints will also be evaluated for the study to include: (a) hematologic response at 3 and 12 months and yearly thereafter; (b) relapse (c) clonal evolution to PNH, myelodysplasia or acute leukemia; (e) survival.

Enrollment: 1
Study Start Date: August 2010
Study Completion Date: July 2012
Primary Completion Date: July 2012 (Final data collection date for primary outcome measure)
Intervention Details:
    Drug: Cyclophosphamide
    N/A
    Drug: Fludarabine
    N/A
  Hide Detailed Description

Detailed Description:

Severe aplastic anemia (SAA) is a life-threatening bone marrow failure disorder characterized by pancytopenia and a hypocellular bone marrow. Allogeneic hematopoietic stem cell transplantation (HSCT) offers the opportunity for cure in 70 percent of patients, but most patients are not suitable candidates for this treatment modality due to advanced age, comorbidities or lack of a histocompatible donor. For these patients, comparable long-term survival is attainable with immunosuppressive treatment (IST) with anti-thymocyte globulin (ATG) and cyclosporine (CsA). However, approximately 1/3 of patients do not show blood count improvement after ATG/CsA and are considered to have refractory disease. Furthermore, analysis of our own extensive clinical data suggests that poor blood count responses to a single course of ATG (nonrobust responders), even when transfusion-independence is achieved, predicts a markedly worse prognosis compared to those who achieve a robust hematologic improvement (protocol 90-H-0146) .

In patients who are refractory to horse ATG (h-ATG) and do not have a histocompatible sibling, alternative donor (AD) HSCT or a repeat course of IST are options. Registry data suggests that outcome for AD HSCT in SAA is not as favorable compared to a matched sibling HSCT with long-term survival at about 40-50 percent and a higher risk of graft-versus-host disease. However, in recent smaller retrospective studies survival after AD HSCT in children rivals that of a sibling transplant when an unrelated donor who matches in 10 HLA loci (matched unrelated donor) is available. With repeat IST, response rates with rabbit anti-thymocyte has varied from 22 percent up to 77 percent. Our experience in refractory SAA (protocol 03-H-0249) is that rabbit ATG + CsA and alemtuzumab are equally efficacious as salvage therapies, with a response rate of about 30 percent for each treatment. For the 20-30 percent of patients who remain refractory after 2 courses of treatment, further courses of IST have been of limited value with responses observed only occasionally. In addition, efforts to improve initial IST in treatment-na ve patients (addition of mycophenolate mofetil and sirolimus) have not yielded promising regimens with activity in SAA (protocols 00-H-0032, 03-H-0193, and 06-H-0034). Therefore, novel regimens are needed to improve outcomes in SAA for those without a histocompatible sibling, which encompass the majority of patients with this disease.

The current limitations of IST in SAA are: 1) the majority of the responses observed following initial h-ATG/CsA are partial with only a few patients achieving normal blood counts; 2) 1/3 of patients are refractory to initial h-ATG/CsA; 3) response rate in these refractory patients who are retreated is only 30 percent; 4) hematologic relapses occur in 35 percent of responders following initial response to h-ATG/CsA; 5) among relapsed patients chronic use of CsA is not infrequent which often leads to toxicities from the long term exposure to this drug (especially in older patients); and 6) clonal evolution is still observed in 10-15% of patients. Towards the goal of addressing these limitations we are proposing a novel regimen of fludarabine (Flu) plus cyclophosphamide (Cy) in SAA patients refractory to horse ATG/CsA. The Hematology Branch has considerable experience with Flu/Cy as part of the condition regimen in allotransplantation protocols (protocols 99-H-0050, 97-H-0196, 99-H-0064, 99-H-0050, 97-H-0196, 02-H-0111, 01-H0162, 03-H-0192, 04-H-0112, 06-H-0248, 07-H-0136). In addition, this regimen has been incorporated into the NCI's Surgery Branch preparative regimen for autologous HSCT prior to infusion of tumor infiltrating lymphocytes. Flu/Cy is well tolerated and a potent immunosuppressive regimen that is not myeloablative. Therefore, we propose to investigate Flu/Cy to address the current limitations of IST in SAA.

The main objective of this study is to assess the safety and efficacy of Flu/Cy in refractory SAA. The primary endpoint will be hematologic response, defined as no longer meeting criteria for SAA, at 6 months. Secondary endpoints are relapse, robustness of hematologic recovery at 6 months, response at 3 months and 12 months, survival, clonal evolution to PNH, myelodysplasia and acute leukemia. The primary endpoint will be changes absolute neutrophil count, platelet count, and reticulocyte count at 6 months. Secondary endpoints will include time to relapse, changes in cytogenetics, and time to death.

  Eligibility

Ages Eligible for Study:   2 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

-INCLUSION CRITERIA:

  1. Severe aplastic anemia characterized by:

    Bone marrow cellularity < 30 percent (excluding lymphocytes)

    AND

    At least two of the following:

    • Absolute neutrophil count < 500/ microL
    • Platelet count < 20,000/ microL
    • Absolute reticulocyte count < 60,000/ microL
  2. Failure to respond to an initial course of h-ATG/CsA at least 3 months post-treatment or a suboptimal response to initial h-ATG/CsA defined by both platelet and reticulocyte count < 50,000 /microL at 3 months post-treatment

    OR

  3. Refractory SAA unresponsive to both horse and rabbit ATG-based regimens
  4. Age greater than or equal to 2 years old
  5. Weight greater than or equal to 12 kg

EXCLUSION CRITERIA:

  1. Diagnosis of Fanconi anemia
  2. Cardiac ejection fraction < 30 percent (evaluated by ECHO)
  3. Evidence of a clonal hematologic bone marrow disorder on cytogenetics. Patients with the presence of trisomy 8, loss of Y or del(20q) will not be excluded in the absence of dysplastic changes in the marrow. Patients with very severe neutropenia (ANC < 200 /microL) will not be excluded initially if cytogenetics are not available or pending. If evidence of a clonal disorder is later identified, the patient will go off study)
  4. Prior immunosuppressive therapy with high dose Cy
  5. Infection not adequately controlled with appropriate therapy
  6. Serologic evidence of HIV infection
  7. Moribund status or concurrent hepatic, renal, cardiac, neurologic, pulmonary, infectious, or metabolic disease of such severity that it would preclude the patient's ability to tolerate protocol therapy, or that death within 30 days is likely
  8. Subjects with cancer who are on active chemotherapeutic treatment or who take drugs with hematological effects
  9. Current pregnancy or unwillingness to take oral contraceptives or refrain from pregnancy if of childbearing potential
  10. Not able to understand the investigational nature of the study or to give informed consent
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01187017

Locations
United States, Maryland
National Institutes of Health Clinical Center, 9000 Rockville Pike
Bethesda, Maryland, United States, 20892
Sponsors and Collaborators
Investigators
Principal Investigator: Danielle M Townsley, M.D. National Heart, Lung, and Blood Institute (NHLBI)
  More Information

Additional Information:
Publications:
Responsible Party: National Institutes of Health Clinical Center (CC) ( National Heart, Lung, and Blood Institute (NHLBI) )
ClinicalTrials.gov Identifier: NCT01187017     History of Changes
Other Study ID Numbers: 100177, 10-H-0177
Study First Received: August 20, 2010
Last Updated: February 8, 2013
Health Authority: United States: Federal Government

Keywords provided by National Institutes of Health Clinical Center (CC):
Severe Aplastic Anemia
Aplastic Anemia
Immunosuppression
Immunosuppressive Therapy
T-Cells

Additional relevant MeSH terms:
Anemia
Anemia, Aplastic
Neutropenia
Pancytopenia
Agranulocytosis
Bone Marrow Diseases
Hematologic Diseases
Leukocyte Disorders
Leukopenia
Cyclophosphamide
Fludarabine
Fludarabine phosphate
Alkylating Agents
Antimetabolites
Antimetabolites, Antineoplastic
Antineoplastic Agents
Antineoplastic Agents, Alkylating
Antirheumatic Agents
Immunologic Factors
Immunosuppressive Agents
Molecular Mechanisms of Pharmacological Action
Myeloablative Agonists
Pharmacologic Actions
Physiological Effects of Drugs
Therapeutic Uses

ClinicalTrials.gov processed this record on October 23, 2014